Literature DB >> 12830463

Incidence of ESRD and survival after renal replacement therapy in patients with type 1 diabetes: a report from the Allegheny County Registry.

Rimei Nishimura1, Janice S Dorman, Zsolt Bosnyak, Naoko Tajima, Dorothy J Becker, Trevor J Orchard.   

Abstract

BACKGROUND: Little information is available regarding the long-term incidence of end-stage renal disease (ESRD) and survival after the introduction of renal replacement therapy (RRT) in patients with type 1 diabetes.
METHODS: We studied 1,075 patients with type 1 diabetes (onset age < 18 years) diagnosed between 1965 and 1979, who comprise the Allegheny County population-based registry. Onset of ESRD was defined as the introduction of RRT (dialysis or transplantation).
RESULTS: Of 1,075 registrants, the living status of 975 patients (90.7%) and complication status of 798 patients (74.2%) were ascertained as of January 1, 1999. During the observation period, 104 patients (13.0%) developed ESRD, for an incidence rate of 521/100,000 person-years (95% confidence interval, 424 to 629). The cumulative incidence of ESRD was 11.3% at 25 years of diabetes. A significant decline was observed in 20-year cumulative incidence rates of ESRD for patients diagnosed between 1965 and 1969, 1970 and 1974, and 1975 and 1979 (9.1%, 4.7%, and 3.6%, respectively; P = 0.006). Of 104 patients with ESRD, 29 patients (28%) received dialysis alone, 44 patients (42%) received dialysis followed by kidney transplantation, 26 patients (25%) underwent successful transplantation alone, and 5 patients (5%) underwent a failed kidney transplantation followed by dialysis therapy. The cumulative survival rate 10 years after the introduction of RRT was 51.2%. The cumulative survival rate of dialysis therapy followed by kidney transplantation was significantly greater than that of dialysis therapy alone (P < 0.001). No difference was detected in survival between pancreas-kidney transplant recipients and kidney-alone transplant recipients (P = 0.7).
CONCLUSION: The incidence of ESRD observed in this cohort has declined, probably reflecting the better glycemic and blood pressure control available since the early 1980s.

Entities:  

Mesh:

Year:  2003        PMID: 12830463     DOI: 10.1016/s0272-6386(03)00414-1

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  15 in total

Review 1.  Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history.

Authors:  Peter Rossing
Journal:  Curr Diab Rep       Date:  2006-12       Impact factor: 4.810

2.  Locus and gene-based GWAS meta-analysis identifies new diabetic nephropathy genes.

Authors:  Mohammad Saeed
Journal:  Immunogenetics       Date:  2017-11-16       Impact factor: 2.846

3.  Patterns of Estimated Glomerular Filtration Rate Decline Leading to End-Stage Renal Disease in Type 1 Diabetes.

Authors:  Jan Skupien; James H Warram; Adam M Smiles; Robert C Stanton; Andrzej S Krolewski
Journal:  Diabetes Care       Date:  2016-09-19       Impact factor: 19.112

Review 4.  The changing epidemiology of diabetic microangiopathy in type 1 diabetes.

Authors:  P Rossing
Journal:  Diabetologia       Date:  2005-06-29       Impact factor: 10.122

Review 5.  Simultaneous pancreas-kidney transplantation: The role in the treatment of type 1 diabetes and end-stage renal disease.

Authors:  Alex T Jiang; Neal Rowe; Alp Sener; Patrick Luke
Journal:  Can Urol Assoc J       Date:  2014-03       Impact factor: 1.862

6.  End-stage renal disease and survival in people with diabetes: a national database linkage study.

Authors:  S Bell; E H Fletcher; I Brady; H C Looker; D Levin; N Joss; J P Traynor; W Metcalfe; B Conway; S Livingstone; G Leese; S Philip; S Wild; N Halbesma; N Sattar; R S Lindsay; J McKnight; D Pearson; H M Colhoun
Journal:  QJM       Date:  2014-08-19

7.  Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes.

Authors:  Marcus G Pezzolesi; G David Poznik; Josyf C Mychaleckyj; Andrew D Paterson; Michelle T Barati; Jon B Klein; Daniel P K Ng; Grzegorz Placha; Luis H Canani; Jacek Bochenski; Daryl Waggott; Michael L Merchant; Bozena Krolewski; Lucia Mirea; Krzysztof Wanic; Pisut Katavetin; Masahiko Kure; Pawel Wolkow; Jonathon S Dunn; Adam Smiles; William H Walker; Andrew P Boright; Shelley B Bull; Alessandro Doria; John J Rogus; Stephen S Rich; James H Warram; Andrzej S Krolewski
Journal:  Diabetes       Date:  2009-02-27       Impact factor: 9.461

8.  Rates of progression in diabetic retinopathy during different time periods: a systematic review and meta-analysis.

Authors:  Tien Y Wong; Mkaya Mwamburi; Ronald Klein; Michael Larsen; Harry Flynn; Marisol Hernandez-Medina; Gayatri Ranganathan; Barbara Wirostko; Andreas Pleil; Paul Mitchell
Journal:  Diabetes Care       Date:  2009-12       Impact factor: 17.152

9.  Improvements in the life expectancy of type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications study cohort.

Authors:  Rachel G Miller; Aaron M Secrest; Ravi K Sharma; Thomas J Songer; Trevor J Orchard
Journal:  Diabetes       Date:  2012-07-30       Impact factor: 9.461

10.  Direct diabetes-related costs in young patients with early-onset, long-lasting type 1 diabetes.

Authors:  Christina Bächle; Andrea Icks; Klaus Straßburger; Marion Flechtner-Mors; Andreas Hungele; Peter Beyer; Kerstin Placzek; Ulrich Hermann; Andrea Schumacher; Markus Freff; Anna Stahl-Pehe; Reinhard W Holl; Joachim Rosenbauer
Journal:  PLoS One       Date:  2013-08-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.